← Back to Search

Monoclonal Antibodies

FB825 for Atopic Dermatitis

Phase 2
Waitlist Available
Led By NienYi Chen, PhD
Research Sponsored by Oneness Biotech Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 2, 3, 15, 29, 57, 85, 113, 141 and 169 days
Awards & highlights

Study Summary

This trial will test if FB825, given through IV, can improve atopic dermatitis symptoms as measured by the Eczema Area and Severity Index.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 2, 3, 15, 29, 57, 85, 113, 141 and 169 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 2, 3, 15, 29, 57, 85, 113, 141 and 169 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The mean change of Eczema Area and Severity Index [EASI] from baseline to Week 16
Secondary outcome measures
Measure the profile of FB825 concentration in blood serum after administrating FB825.
Proportion of patients with Eczema Area and Severity Index [EASI-90] ( ≥90 % improvement from baseline) at Weeks 2, 4, 8, 12, 16, 20 and 24
Proportion of patients with Eczema Area and Severity Index≥50% [ EASI-50] ( ≥50% improvement from baseline) at Weeks 2, 4, 8, 12, 16, 20 and 24
+9 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: FB825Active Control1 Intervention
FB825
Group II: PlaceboPlacebo Group1 Intervention
Formulation buffer

Find a Location

Who is running the clinical trial?

Oneness Biotech Co., Ltd.Lead Sponsor
18 Previous Clinical Trials
1,145 Total Patients Enrolled
NienYi Chen, PhDPrincipal InvestigatorOneness Biotech
2 Previous Clinical Trials
140 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
2020. "Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04413942.
All > Seborrheic Dermatitis > Atopic Dermatitis
~19 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top